Revolution Medicines price target raised to $265
Benzinga reported that B of A Securities raised its price target on Revolution Medicines to $265.00 per share from $225.00.
Benzinga reported that B of A Securities raised its price target on Revolution Medicines to $265.00 per share from $225.00.